Literature DB >> 21881372

Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension : a systematic review.

Mohammad Rahnavardi1, Tristan D Yan, Christopher Cao, Michael P Vallely, Paul G Bannon, Michael K Wilson.   

Abstract

PURPOSE: Pulmonary thromboendarterectomy (PTE) is a treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). The present systematic review was performed to assess the safety and efficacy of PTE for CTEPH.
METHODS: A systematic review was performed, and six electronic databases were searched for published studies from January 1999 to February 2010. All articles that presented morbidity and mortality data, survival data or preoperative and postoperative pulmonary hemodynamic indices were included. The primary outcome measures extracted were early morbidity and mortality, pulmonary hemodynamic and functional outcome indices prior to and after the operation, and survival data.
RESULTS: Of the 654 publications retrieved, 19 relevant papers (total number of 2729 patients) representing the most recent and complete data set from each institute, were included for appraisal and data extraction. No randomized controlled trials or matched comparative studies were identified. Thirty-day mortality ranged from 1.3% to 24% (median 8%). Residual pulmonary hypertension was reported in 11%-35% of patients after PTE. Pulmonary artery pressure and pulmonary vascular resistance significantly decreased after PTE in all studies. Before PTE, 60%-100% of patients were in NYHA functional class III or IV. This percentage decreased to 0%-21% after PTE. Five-year survival ranged from 74% to 89%.
CONCLUSIONS: The current literature suggests that PTE for patients with CTEPH is associated with acceptable perioperative morbidity and mortality rates and improved hemodynamic indices and survival when viewed against the prognosis associated with historical controls using medical therapy.

Entities:  

Mesh:

Year:  2011        PMID: 21881372     DOI: 10.5761/atcs.oa.10.01653

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  16 in total

1.  Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.

Authors:  John E Cannon; Li Su; David G Kiely; Kathleen Page; Mark Toshner; Emilia Swietlik; Carmen Treacy; Anie Ponnaberanam; Robin Condliffe; Karen Sheares; Dolores Taboada; John Dunning; Steven Tsui; Choo Ng; Deepa Gopalan; Nicholas Screaton; Charlie Elliot; Simon Gibbs; Luke Howard; Paul Corris; James Lordan; Martin Johnson; Andrew Peacock; Robert MacKenzie-Ross; Benji Schreiber; Gerry Coghlan; Kostas Dimopoulos; Stephen J Wort; Sean Gaine; Shahin Moledina; David P Jenkins; Joanna Pepke-Zaba
Journal:  Circulation       Date:  2016-04-06       Impact factor: 29.690

2.  Neutrophil/Lymphocyte Ratio Can Predict Postoperative Mortality in Patients with Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Mehmed Yanartas; Mehmet Emin Kalkan; Akin Arslan; Serpil Gezer Tas; Cengiz Koksal; Nural Bekiroglu; Bedrettin Yildizeli
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-09       Impact factor: 1.520

3.  Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Muhammad Shahzeb Khan; Emaan Amin; Muhammad Mustafa Memon; Naser Yamani; Tariq Jamal Siddiqi; Safi U Khan; Mohammad Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Rami Doukky; Raymond L Benza; Richard A Krasuski
Journal:  Int J Cardiol       Date:  2019-02-23       Impact factor: 4.164

Review 4.  Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  A Dasgupta; L Bowman; C L D'Arsigny; S L Archer
Journal:  Clin Pharmacol Ther       Date:  2014-11-28       Impact factor: 6.875

5.  Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience.

Authors:  María Jesús López-Gude; Isabel Blanco; Victoria Benito-Arnáiz; Manel Castellà; Pilar Escribano-Subías; Clara Martin; Joan Albert Barberà; José María Cortina-Romero
Journal:  Ann Cardiothorac Surg       Date:  2022-03

6.  Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review.

Authors:  John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2022-03

Review 7.  Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.

Authors:  David S Poch; William R Auger
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

8.  2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Authors:  Chih-Hsin Hsu; Wan-Jing Ho; Wei-Chun Huang; Yu-Wei Chiu; Tsu-Shiu Hsu; Ping-Hung Kuo; Hsao-Hsun Hsu; Jia-Kan Chang; Chin-Chang Cheng; Chao-Lun Lai; Kae-Woei Liang; Shoa-Lin Lin; Hsao-Hsun Sung; Wei-Chuan Tsai; Ken-Pen Weng; Kai-Sheng Hsieh; Wei-Hsian Yin; Shing-Jong Lin; Kuo-Yang Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

9.  Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.

Authors:  Takeshi Ogo; Hiroto Shimokawahara; Hideyuki Kinoshita; Seiichiro Sakao; Kohtaro Abe; Satoaki Matoba; Hirohiko Motoki; Noriaki Takama; Junya Ako; Yasuhiro Ikeda; Shuji Joho; Hisataka Maki; Takahiro Saeki; Teruyasu Sugano; Ichizo Tsujino; Koichiro Yoshioka; Naoki Shiota; Shinichi Tanaka; Chieko Yamamoto; Nobuhiro Tanabe; Koichiro Tatsumi
Journal:  Eur Respir J       Date:  2022-07-07       Impact factor: 33.795

10.  Clinical and hemodynamic outcomes and mortality risk factors in patients undergoing pulmonary thromboendarterectomy.

Authors:  Cristhian F Ramirez-Ramos; Clara Saldarriaga-Giraldo; Manuela Yepes-Calderon; Gustavo Castilla-Agudelo; Mateo Aranzazu-Uribe; Santiago Saldarriaga-Betancur; Paulina Castro; Alejandro Londoño; Hector Ortega; Jorge Zapata-Sanchez; Eliana Cañas; Juan C Rendon-Isaza
Journal:  Arch Cardiol Mex       Date:  2022-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.